retatrutide mechanism triple agonist glp-1 gip glucagon receptor just had its biggest data year yet. In 2026, Eli Lilly's GLP-1/GIP/glucagon posted two major Phase 3 readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight The Road towards Triple Agonists:
Description
10.1080/15548627.2020.1731270 34 JastreboffA

European Journal of Clinical Nutrition

Side effects remain one of the primary drivers of discontinuation

Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus

What Does the Science Say
